| Original language | English (US) |
|---|---|
| Pages (from-to) | S2-S7 |
| Journal | Molecular Genetics and Metabolism |
| Volume | 108 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2013 |
Bibliographical note
Funding Information:The WORLD Symposium™ has become the major educational and unifying activity of the Network, and has evolved into a highly interactive research activity. The Symposium is in its third year of being co-organized by NIH with funding from the National Institute of Neurological Disorders and Stroke (NINDS), — in collaboration with the Lysosomal Disease Network, also funded by NINDS, — the National Institute of Diabetes and Digestive Diseases (NIDDK), the NIH Office of Rare Disease Research (ORDR) at National Center for Translational Research (NCATS). The underlying theme “transitioning molecular biology to human therapies” seeks to elucidate the challenges, and highlight the successes, in bringing bench discoveries into successful clinical therapies. The main emphasis of the meeting remains the same: to assess the mechanisms, and obstacles, for taking bench research into human therapy. This year, the program is assembled almost entirely from submitted research abstracts with only three Invited Speakers. This allows for a larger and more diverse representation of the work being done in the field. The number of abstracts submitted has continued to grow dramatically ( Fig. 1 ). The first day is focused on basic research, the second day on translational research, and the third on clinical research. This day-by-day progression through the three stages of research, is a signature feature of the WORLD Symposium™ and is enthusiastically received based on attendee evaluation.